{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-254149","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2021-08-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.457717+00:00","generated_at":"2026-06-29T08:26:22.636890+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"BridgeBio appoints Fred Hassan, Andrea Ellis, and Douglas Dachille to board of directors","bullets":["Board expanded from 11 to 14 members; three new independent directors effective August 17, 2021.","Fred Hassan, former Schering-Plough CEO and Warburg Pincus director, appointed as Class II director.","Andrea Ellis, CFO of Lime and former Goldman Sachs banker, appointed as Class II director and audit committee member.","Douglas Dachille, former AIG CIO, appointed as Class III director; previously served as board observer.","Each director granted option to purchase $1.2M of common stock at $49.54, vesting over three years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-254149","json":"https://secwatch.observer/filing/0001193125-21-254149.json","markdown":"https://secwatch.observer/filing/0001193125-21-254149.md","text":"https://secwatch.observer/filing/0001193125-21-254149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000119312521254149/0001193125-21-254149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000119312521254149/d219643d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T08:26:22.636890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a888ebbca","claim":"Fred Hassan was appointed as Director at BridgeBio Pharma, Inc..","evidence_excerpt":"the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000119312521254149/0001193125-21-254149-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1978306974","claim":"Andrea Ellis was appointed as Director at BridgeBio Pharma, Inc..","evidence_excerpt":"the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000119312521254149/0001193125-21-254149-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3b18f43d49","claim":"Douglas Dachille was appointed as Director at BridgeBio Pharma, Inc..","evidence_excerpt":"the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000119312521254149/0001193125-21-254149-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}